Clinical Trial Update: 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating 177Lu-PSMA-617 as a systemic adjuvant treatment for high and very high risk prostate cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING